Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 3/17/20 (What's New)


  • Boosted PI monotherapy for maintenance of virologic suppression is an investigational therapeutic strategy that takes advantage of the very high genetic barrier to resistance of boosted PIs 
  • Lopinavir/Ritonavir Monotherapy
    • Only 10% of virologically suppressed patients receiving lopinavir/ritonavir plus 2 NRTIs switched to lopinavir/ritonavir monotherapy experienced viral rebound if they had been virologically suppressed for ≥ 6 months before switching[Bierman 2009]
      • Patients experiencing virologic rebound were able to reattain virologic suppression with the reintroduction of NRTIs[Bierman 2009; Mathis 2011]
    Atazanavir/Ritonavir Monotherapy
      Darunavir/Ritonavir Monotherapy

      Action required